Kymera Therapeutics's top three insider shareholders as of April 17, 2026 are Bros. Advisors Lp Baker (Director, 7.96Mn shares), Venture Fund X, L.P. Atlas (TenPercentOwner, 5.50Mn shares), Venture Fund X, L.P. Atlas (TenPercentOwner, 5.50Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Bros. Advisors Lp Baker | - | 0 | 7,955,916 | 11 Dec, 2025 |
| Venture Fund X, L.P. Atlas | - | 4,676,075 | 828,830 | 13 Mar, 2024 |
| Venture Fund X, L.P. Atlas | - | 4,676,075 | 828,830 | 13 Mar, 2024 |
| Venture Fund X, L.P. Atlas | - | 0 | 1,049,540 | 01 Nov, 2022 |
| Venture Fund X, L.P. Atlas | - | 0 | 1,049,540 | 01 Nov, 2022 |
| Bruce Booth | - | 0 | 1,049,540 | 01 Nov, 2022 |
| Bruce Booth | - | 0 | 819,151 | 15 Mar, 2024 |
| Bruce Booth | - | 0 | 675,341 | 04 Mar, 2026 |
| Nello Mainolfi | Chief Executive Officer | 666,195 | 0 | 25 Feb, 2026 |
| Nello Mainolfi | Chief Executive Officer | 666,195 | 0 | 25 Feb, 2026 |
| Partners L P/Il Bvf | - | 353,412 | 0 | 01 Jul, 2025 |
| Partners L P/Il Bvf | - | 353,412 | 0 | 01 Jul, 2025 |
| Partners L P/Il Bvf | - | 353,412 | 0 | 01 Jul, 2025 |
| Partners L P/Il Bvf | - | 353,412 | 0 | 01 Jul, 2025 |
| Bruce N. Jacobs | Chief Financial Officer | 232,588 | 0 | 04 Mar, 2026 |
| Jared Gollob | Chief Medical Officer | 117,134 | 0 | 04 Mar, 2026 |
| Ellen Chiniara | Chief Legal Officer | 80,085 | 0 | 03 Mar, 2025 |
| Jeremy G Chadwick | Chief Operating Officer | 61,202 | 0 | 01 Apr, 2026 |
| Brian Adams | Chief Legal Officer | 56,625 | 0 | 04 Mar, 2026 |
| Noah Goodman | Chief Business Officer | 51,542 | 0 | 10 Apr, 2026 |
| Elaine Caughey | Chief Business Officer | 18,986 | 0 | 03 Mar, 2023 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 09 Apr, 2026 | Noah Goodman | Common Stock | A | 2,500 | $21.05 | 61,806 | D | M |
| 09 Apr, 2026 | Noah Goodman | Common Stock | D | 3,094 | $86.62 | 58,712 | D | S |
| 09 Apr, 2026 | Noah Goodman | Common Stock | D | 2,670 | $87.11 | 56,042 | D | S |
| 09 Apr, 2026 | Noah Goodman | Common Stock | D | 2,500 | $89.00 | 53,542 | D | S |
| 10 Apr, 2026 | Noah Goodman | Common Stock | D | 2,000 | $87.35 | 51,542 | D | S |
| 09 Apr, 2026 | Noah Goodman | Stock Option (Right to Buy) | D | 2,500 | $0.00 | 97,500 | D | M |
| 31 Mar, 2026 | Jeremy G Chadwick | Common Stock | A | 7,600 | $29.64 | 68,802 | D | M |
| 31 Mar, 2026 | Elena Ridloff | Common Stock | A | 7,400 | $14.18 | 7,400 | D | M |
| 31 Mar, 2026 | Jeremy G Chadwick | Common Stock | D | 7,600 | $85.38 | 61,202 | D | S |
| 31 Mar, 2026 | Elena Ridloff | Common Stock | D | 7,400 | $85.37 | 0 | D | S |
| 01 Apr, 2026 | Jeremy G Chadwick | Common Stock | A | 14,640 | $29.64 | 75,842 | D | M |
| 01 Apr, 2026 | Elena Ridloff | Common Stock | A | 4,600 | $14.18 | 4,600 | D | M |
| 01 Apr, 2026 | Jeremy G Chadwick | Common Stock | D | 13,540 | $85.41 | 62,302 | D | S |
| 01 Apr, 2026 | Elena Ridloff | Common Stock | D | 3,400 | $85.19 | 1,200 | D | S |
| 01 Apr, 2026 | Jeremy G Chadwick | Common Stock | D | 1,100 | $86.05 | 61,202 | D | S |
| 01 Apr, 2026 | Elena Ridloff | Common Stock | D | 1,200 | $86.05 | 0 | D | S |
| 31 Mar, 2026 | Elena Ridloff | Stock Option (Right to Buy) | D | 7,400 | $0.00 | 4,600 | D | M |
| 31 Mar, 2026 | Jeremy G Chadwick | Stock Option (Right to Buy) | D | 7,600 | $0.00 | 83,273 | D | M |
| 01 Apr, 2026 | Elena Ridloff | Stock Option (Right to Buy) | D | 4,600 | $0.00 | 0 | D | M |
| 01 Apr, 2026 | Jeremy G Chadwick | Stock Option (Right to Buy) | D | 14,640 | $0.00 | 68,633 | D | M |